AstraZeneca, Eli Lilly terminate clinical trials of Alzheimer’s disease treatment lanabecestat
An independent data monitoring committee (IDMC) has recommended the partnership to stop the trials of lanabecestat, as it is unlikely to meet primary endpoints. AstraZeneca IMED biotech unit